Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2010

View Archived Issues

Azathioprine and prednisolone reduce relapse rates in neuromyelitis optica

Antibodies targeting LINGO-1 promote myelination in preclinical studies

Manageable toxicity seen with brivanib alaninate plus cetuximab and irinotecan in colorectal cancer

New modulators of G protein-coupled receptors disclosed

QLT expands phase Ib study of QLT-091001 to include patients with retinitis pigmentosa

Afatinib is active in patients with head and neck and lung cancers

Clinical data reported on cilengitide in NSCLC and glioblastoma

Incuron initiates phase Ib trial of Curaxin CBLC-102 in liver tumors

Orphan drug status granted for PRX-8066 in PAH

Merck KGaA describes novel E-NPP 2 inhibitors

Cipher completes patient enrollment in phase III CIP-Isotretinoin study

New benzoxazole derivatives disclosed by BioMarin IGA

Protalix BioTherapeutics reports on taliglucerase alfa switchover trial

NuPathe submits Zelrix NDA to FDA for migraine

Novartis and Xenon Pharma claim new acyl-CoA desaturase inhibitors

FDA responds to Biodel regarding Linjeta NDA

New neuropeptide Y5 receptor antagonists discovered

Compugen licenses MAb-based oncology target to Seattle Genetics

VaxGen changes name to diaDexus

NeoPharm merges with Insys Therapeutics

Cell Therapeutics submits MAA to EMA for Pixuvri in NHL

Genta receives EMA advice for phase III tesetaxel trial in gastric cancer

Covance and sanofi-aventis enter 10-year strategic collaboration

FDA orphan drug status for ensituximab in pancreatic cancer

FluCide extends survival of animals in influenza study

GSK receives Japanese approval for Revolade and Xyzal

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...